Doxazosin in patients with hypertension
| Autor: | Mary J. Mackie, F. C. Falkner, Paula V. Mayshar, J. D. Lazar, Timothy C. Fagan, Kenneth A. Conrad, J. F. Souhrada, Stanley M. Lee |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male medicine.medical_treatment Blood Pressure Bioequivalence Pharmacology urologic and male genital diseases Pharmacokinetics Heart Rate Oral administration Doxazosin Humans Medicine Pharmacology (medical) In patient Adverse effect Alpha adrenergic blockade Antihypertensive Agents Chemotherapy business.industry Prazosin General Medicine Middle Aged Hypertension Female business Half-Life medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 35:21-24 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf00555502 |
| Popis: | The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients. For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h. The mean terminal elimination half-life was 22 h. The four tablets containing 1, 2, 4, or 8 mg of doxazosin were bioequivalent in delivering the 8 mg dose. In patients with mild to moderate hypertension, 26-day treatment with doxazosin resulted in blood pressure reduction of 10/7 mmHg in the supine and 13/18 mmHg in the standing position. Adverse effects were generally mild and of brief duration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink